| 1 Bagadi S A R, Prasad C P, Srivastava A, et al. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer［J］. Breast Cancer Research and Treatment, 2007, 104(3): 277～286.2 Cui M, Liu Z H, Qin Q, et al. Tumour induction in rats following exposure to short-term high dose aristolochic acid Ⅰ［J］. Mutagenesis, 2005, 20(1): 45～49.3 Debelle F D, Vanherweghem J L. Aristolochic acid nephropathy: A worldwide problem［J］. Kidney Int, 2008, 74(2): 158～169.4 Depierreux M, Van Damme B, Vanden Houte K, et al. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs［J］. Am J Kidney Dis, 1994, 24(2): 172～180.5 Grollman A P, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy［J］. Proc Natl Acad Sci USA, 2007, 104: 12129～12134.6 Hocevar B A, Smine A, Xu X X, et al. The adaptor molecule Disabled-2 links the transforming growth factor β receptors to the Smad pathway［J］. The EMBO Journal, 2001, 20(11): 2789～2801.7 Hocevar B A, Mou F, Rennolds J L, et al. Regulation of the Wnt signaling pathway by disabled-2 (Dab2)［J］. The EMBO Journal, 2003, 22(12): 3084～3094.8 Hocevar B A, Prunier C, Howe P H, et al. Disabled-2 (Dab2) mediates transforming growth factor β(TGF-β)-stimulated fibronectin synthesis through TGF-β-activated kinase 1 and activation of the JNK pathway［J］. Journal of Biological Chemistry, 2005, 280: 25920～25927.9 Karam J A, Shariat S F, Huang H Y, et al. Decreased DOC-2/DAB-2 expression in urothelial caricinoma of the bladder［J］. Clin Cancr Res, 2007, 13: 4400～4406.10 Lemy A, Wissing K M, Rorive S, et al. Late onset of bladder urothelial carcinoma after renal transplantation for end-stage aristolochic acid nephropathy: A case series with 15-year follow-up［J］. Am J Kidney Dis, 2008, 51(3): 471～477.11 Li J, Zhang Z, Wu G, et al. TGF-β1/Smads signaling stimulates renal interstitial fibrosis in experimental AAN［J］. Journal of Receptors and Signal Transduction, 2009, 29(5): 280～285.12 Lord G M, Hollstein M, Arlt V M, et al. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy［J］. American Journal of Kidney Disease, 2004, 43(4): 11～17.13 Mishra S K, Keyel P A, Hawryluk M J, et al. Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor［J］. The EMBO Journal, 2002, 21: 4915～4926.14 Mok S C, Wong K K, Chan R K W, et al. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer［J］. Gynecologic Oncology, 1994, 52(2): 247～252.15 Morris S M, Cooper J A. Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2［J］. Traffic, 2001, 2: 111～123.16 Nagai J, Christensen E I, Morris S M, et al. Mutually dependent localization of megalin and Dab2 in the renal proximal tubule［J］. Am J Physiol Physiol, 2005, 289: 569～576.17 Penheiter S G, Singh R D, Repellin C E, et al. Type Ⅱ transforming growth factor-β receptor recycling is dependent upon the clathrin adaptor protein Dab2［J］. Molecular Biology of the Cell, 2010, 21: 4009～4019.18 Pozdzik A A, Salmon I J, Debelle F D, et al. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation［J］. Kidney Int, 2008a, 73: 595～607.19 Pozdzik A A, Salmon I J, Husson C P, et al. Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy［J］. Nephrol Dial Transplant, 2008b, 23: 2480～2491.20 Prunier C, Howe P H. Disabled-2 (Dab2) is required for transforming growth factor β-induced epithelial to mesenchymal transition (EMT)［J］. J Biol Chem, 2005, 280: 17540～17548.21 Schmeiser H H, Bieler C A, Weissler M, et al. Detection of DNA adducts formed by aristolchic acid in renal tissue from patients with Chinese herbs nephropathy［J］. Cancer Res, 1996, 56: 2025～2028.22 Shibutani S, Dong H, Suzuki N, et al. Selective toxicity of aristolochic acids Ⅰ and Ⅱ［J］. Drug Metab Dispos, 2007, 35: 1217～1222.23 Vanherweghem J L. Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including chinesis herbs［J］. Lancet, 1993, 341: 387.24 Vanherweghem J L, Tielemans C, Simon J, et al. Chinese herbs nephropathy and renal pelvic carcinoma［J］. Nephrol Dial Transplant, 1995, 10: 270～273.25 Yan X H, Chen Y G. Smad7: Not only a regulator, but also a cross-talk mediator of TGF-β signalling［J］. Biochem, 2011, 434: 1～10.26 Yang F, Chung A C, Huang X R, et al. Angiotensin Ⅱ induces connective tissue growth factor and collagen Ⅰ expression via transforming growth factor-beta-dependent and-independent Smad pathways: The role of Smad3［J］. Hypertension, 2009, 54: 877～884. |
